4.8 Article

Activation of a cryptic 5′ splice site reverses the impact of pathogenic splice site mutations in the spinal muscular atrophy gene

Journal

NUCLEIC ACIDS RESEARCH
Volume 45, Issue 21, Pages 12214-12240

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkx824

Keywords

-

Funding

  1. National Institutes of Health [R01 NS055925, R21 NS101312]
  2. Iowa Center for Advanced Neurotoxicology (ICAN)
  3. NIH [R01 NS055925, R21 NS101312]
  4. Salsbury Endowment (Iowa State University, Ames, IA, USA)

Ask authors/readers for more resources

Spinal muscular atrophy (SMA) is caused by deletions or mutations of the Survival Motor Neuron 1 (SMN1) gene coupled with predominant skipping of SMN2 exon 7. The only approved SMA treatment is an antisense oligonucleotide that targets the intronic splicing silencer N1 (ISS-N1), located downstream of the 5' splice site (5' ss) of exon 7. Here, we describe a novel approach to exon 7 splicing modulation through activation of a cryptic 5' ss (Cr1). We discovered the activation of Cr1 in transcripts derived fromSMN1 that carries a pathogenic G-to-Cmutation at the first position (G1C) of intron 7. We show that Cr1-activating engineered U1 snRNAs (eU1s) have the unique ability to reprogram pre-mRNA splicing and restore exon 7 inclusion in SMN1 carrying a broad spectrum of pathogenic mutations at both the 3' ss and 5' ss of the exon 7. Employing a splicingcoupled translation reporter, we demonstrate that mRNAs generated by an eU1-induced activation of Cr1 produce full-length SMN. Our findings underscore a wider role for U1 snRNP in splicing regulation and reveal a novel approach for the restoration of SMN exon 7 inclusion for a potential therapy of SMA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy

N. N. Singh, M. D. Howell, E. J. Androphy, R. N. Singh

GENE THERAPY (2017)

Article Biochemistry & Molecular Biology

High-affinity RNA targets of the Survival Motor Neuron protein reveal diverse preferences for sequence and structural motifs

Eric W. Ottesen, Natalia N. Singh, Diou Luo, Ravindra N. Singh

NUCLEIC ACIDS RESEARCH (2018)

Article Biochemistry & Molecular Biology

Human Survival Motor Neuron genes generate a vast repertoire of circular RNAs

Eric W. Ottesen, Diou Luo, Joonbae Seo, Natalia N. Singh, Ravindra N. Singh

NUCLEIC ACIDS RESEARCH (2019)

Review Biochemistry & Molecular Biology

A novel role of U1 snRNP: Splice site selection from a distance

Ravindra N. Singh, Natalia N. Singh

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2019)

Article Biochemistry & Molecular Biology

How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene

Natalia N. Singh, Ravindra N. Singh

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2019)

Editorial Material Biochemistry & Molecular Biology

RNA structure and splicing regulation

Francisco E. Baralle, Ravindra N. Singh, Stefan Stamm

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2019)

Editorial Material Chemistry, Medicinal

More is needed to complement the available therapies of spinal muscular atrophy

Ravindra N. Singh

FUTURE MEDICINAL CHEMISTRY (2019)

Review Biochemistry & Molecular Biology

A survey of transcripts generated by spinal muscular atrophy genes

Natalia N. Singh, Eric W. Ottesen, Ravindra N. Singh

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2020)

Review Pharmacology & Pharmacy

RNA in spinal muscular atrophy: therapeutic implications of targeting

Ravindra N. Singh, Joonbae Seo, Natalia N. Singh

EXPERT OPINION ON THERAPEUTIC TARGETS (2020)

Review Cell Biology

Characteristics of circular RNAs generated by human Survival Motor Neuron genes

Eric W. Ottesen, Ravindra N. Singh

CELLULAR SIGNALLING (2020)

Article Biochemistry & Molecular Biology

Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes

Natalia N. Singh, Shaine Hoffman, Prabhakara P. Reddi, Ravindra N. Singh

Summary: Spinal muscular atrophy (SMA) is a major genetic disorder associated with infant mortality, primarily caused by deletions or mutations in the Survival Motor Neuron 1 (SMN1) gene. The spectrum of SMA ranges from prenatal death to survival into adulthood, with all tissues potentially affected.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)

Article Biochemistry & Molecular Biology

High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome

Eric William Ottesen, Diou Luo, Natalia Nikolaevna Singh, Ravindra Narayan Singh

Summary: The intronic splicing silencer N1 (ISS-N1) within Survival Motor Neuron 2 (SMN2) intron 7 is a therapeutic target for treating spinal muscular atrophy. Treatment with 100 nM of Anti-N1 resulted in substantial stimulation of SMN2 exon 7 inclusion but also caused significant perturbations in the transcriptome and widespread aberrant splicing. Shorter ISS-N1-targeting ASOs showed a substantial reduction in off-target effects, providing important insights for better ASO design and dosing regimens of ASO-based drugs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Genetics & Heredity

Internal Introns Promote Backsplicing to Generate Circular RNAs from Spinal Muscular Atrophy Gene

Diou Luo, Natalia Nikolaevna Singh, Ravindra Narayan Singh

Summary: This study investigates the generation mechanism of circRNA in SMN genes. It finds that the presence of introns enhances the rate of circRNA generation and that the exon junction complex plays a role in the generation of circRNAs containing only exons. In addition, SMN circRNAs are preferentially localized in the cytoplasm.

GENES (2022)

Article Biochemistry & Molecular Biology

Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy

Eric W. Ottesen, Natalia N. Singh, Diou Luo, Bailey Kaas, Benjamin J. Gillette, Joonbae Seo, Hannah J. Jorgensen, Ravindra N. Singh

Summary: Designing an RNA-interacting molecule that exhibits both high therapeutic efficacy and concentration-specific specificity remains challenging. Risdiplam and branaplam, two small molecules approved for the treatment of spinal muscular atrophy (SMA) and undergoing clinical trials, respectively, are able to restore the inclusion of Survival Motor Neuron 2 (SMN2) exon 7. However, the transcriptome-wide off-target effects of these compounds in SMA patient cells reveal concentration-dependent changes and perturbations in gene expression, splicing events, and cellular pathways. Understanding these off-target effects and their mechanisms can guide the development of improved dosing regimens and future small molecule therapeutics for splicing modulation.

NUCLEIC ACIDS RESEARCH (2023)

Review Neurosciences

The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy

Ravindra N. Singh, Eric W. Ottesen, Natalia N. Singh

NEUROSCIENCE INSIGHTS (2020)

No Data Available